Preview

Rational Pharmacotherapy in Cardiology

Advanced search

FIVE-YEAR DYNAMICS OF SECONDARY PREVENTION IN PATIENTS WITH STABLE ANGINA AT SPECIALIZED OUT-PATIENT LEVEL IN MOSCOW (PHARMACOEPIDEMIOLOGY STUDY)

https://doi.org/10.20996/1819-6446-2018-14-2-244-251

Full Text:

Abstract

Aim. To assess five-year trend in terms of specialists’ adherence to guidelines on secondary prevention of cardiovascular diseases in patients with stable angina on the level of out-patient specialized healthcare institution in Moscow.

Material and methods. Two-stage retrospective pharmacoepidemiological study was conducted. The object of the study – patient medical records. At the first stage of the study medical records of 2915 patients with stable angina visited the healthcare institution for the first time in 2006 were included, at the second stage – medical records of 1633 patients with stable angina with primary visit in 2011.

Results. Over the five-year period prescription rates of drugs improving prognosis in patients with stable angina significantly increased: antiplatelets – up to 82.7%, beta-blockers – up to 74.3%, statins – up to 45.6%. Despite of no changes registered in prescription rate of the ACE inhibitors, marked increase up to 14.7% in prescription rate of angiotensin receptor blockers was revealed. In the prescription structure of pharmacological groups changes were detected concerning the preferred choice of a specific drug. Due to implementation of dual antiplatelet therapy into clinical practice a reduced number of recommendations of acetylsalicylic acid as monotherapy (down to 93.0%) and increased – in combination with clopidogrel (up to 5.4%) was registered at the second stage of the study. Over a five-year period bisoprolol (55.0%) occupied the leading position in the group of beta-blockers. Metoprolol’s prescription rate decreased to 27.4%. Prescription rate of atenolol decreased down to 3.1%, while that of nebivolol increased up to 8.3%. When choosing among statins specialists recommended significantly more often atorvastatin (up to 52.9%). In the group of ACE inhibitors three drugs preserved their leading positions. Meanwhile the number of recommendations of enalapril increased up to 50.8%, perindopril – up to 24.1%. Analysis of prescribed doses revealed significant increase in recommendations of specific drugs in higher daily doses: acetylsalicylic acid 100 mg – up to 71.1%, simvastatin and atorvastatin 20 mg – up to 60.5% and 41.9%, respectively. When prescribing beta-blockers and ACE inhibitors specialists continued to use minimal and medium therapeutic doses, possibly due to dose titration in patients with comorbidities.

Conclusion. Study results demonstrated positive trend in terms of specialists’ adherence to guidelines on secondary prevention of cardiovascular diseases in patients with stable angina. However, a number of problem aspects were identified that require further optimization of medical and preventive measures in healthcare institutions.

About the Authors

S. В. Fitilev
Peoples' Friendship University of Russia (RUDN University)
Russian Federation

Sergey B. Fitilev – MD, PhD, Professior, Corresponding Member of the Russian Academy of Natural Sciences, Chair of General and Clinical Pharmacology, Medical Institute

Miklukho-Maklaya ul. 6, Moscow, 117198



I. I. Shkrebneva
Peoples' Friendship University of Russia (RUDN University)
Russian Federation

Irina I. Shkrebneva – MD, PhD, Associate Professor, Chair of General and Clinical Pharmacology, Medical Institute

Miklukho-Maklaya ul. 6, Moscow, 117198



A. V. Vozzhaev
Peoples' Friendship University of Russia (RUDN University)
Russian Federation

Alexandr V. Vozzhaev – PhD (Biology), Associate Professor, Chair of General and Clinical Pharmacology, Medical Institute

Miklukho-Maklaya ul. 6, Moscow, 117198



K. O. Tsukanova
Peoples' Friendship University of Russia (RUDN University)
Russian Federation

Kristina O. Tsukanova – MD, Graduate Student, Chair of General and Clinical Pharmacology, Medical Institute

Miklukho-Maklaya ul. 6, Moscow, 117198



References

1. Shalnova S.A., Deev A.D. Russian mortality trends in the early XXI century: official statistics data. Cardiovascular Therapy and Prevention. 2011;10(6):5-10. (In Russ.)

2. Mathers C.D.,Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PloS Med. 2006;3 (11):442. doi: 10.1371/journal.pmed.0030442.

3. Shalnova S.A., Oganov R.G., Steg P.G., Ford I. Coronary heart disease in Russia: today’s reality evidenced by the international CLARIFY registry. Kardiologiia. 2013;53(8):28-33. (In Russ.)

4. Lupanov V.P. Secondary drug prevention of coronary heart disease and myocardial infarction. Meditsinsky Sovet. 2013;3:86-91. (In Russ.)

5. Mainz J. Defining and classifying clinical indicators for quality improvement. Int J QualHealyh Care. 2003;15(6):523-530. doi: 10.1093/intqhc/mzg081.

6. Yusuf S., Islam S., Chow C.K. et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378(9798):1231-1243. doi: 10.1016/S01406736(11)61215-4.

7. Oganov R.G., Shal'nova S.A., Kalinina A.M. Prevention of cardiovascular disease: a guide. Moscow: GEOTAR-Media; 2009. (In Russ.)

8. Oganov R.G., Lepakhin V.K., Fitilev S.B., et al. Diagnosis and therapy of stable angina in Russian Federation (International Study ATP — angina treatment pattern). Kardiologiia. 2003;43(5):9—15. (In Russ.)

9. Fitilev S.B., Vozzhaev A.V., Shkrebniova I.I., Titarova Y.Y., et al comparison of medicamental secondary prevention of cardiovascular disease in ambulatory patients with myocardial infarction over a period of 2001-2006 (pharmacoepidemiological study). Vestnik Rossiiskogo Universiteta Druzhby Narodov. 2009;3:34-6. (In Russ.)

10. Diagnosis and treatment of stable angina pectoris. Russian recommendations. Cardiovascular Therapy and Prevention. 2004;3(4) suppl 1:1-26. (In Russ.)

11. Diagnosis and treatment of stable angina pectoris. Russian recommendations (second revision). Cardiovascular Therapy and Prevention. 2008;7(6) suppl 4:40. (In Russ.)

12. National recommendations for rational pharmacotherapy of cardiovascular diseases (2009). Available at: http://www.scardio.ru/content/images/recommendation/recomendaciifarma.doc. Checked by Mar 24,2018. (In Russ.)

13. Backer G., Ambrosioni E., Borch-Johnsen K., et al. European guidelines on cardiovascular prevention in clinical practice: recommendations of the Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. European Heart Journal. 2003;24(17):1601-10. doi: 10.1016/S0195-668X(03)00347-6.

14. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Guidelines on the management of stable angina pectoris: executive summary. Eur Heart J. 2006;27:1341-81. doi: 10.1093/eurheartj/ehl001.

15. Kotseva K., Wood D. Bacquer D. et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23(6):636-648. doi: 10.1177/2047487315569401.

16. Antithrombotic Trials Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86. doi: 10.1136/bmj.324.7329.71.

17. Tolpygina S.N., Martsevich S.Y. Study of a trend in the frequency of using main drug classes indicated for the treatment of patients with chronic coronary heart disease in 2004 to 2014. Data from the CHD prognosis registry. Klinitsist. 2016;1:29-35. (In Russ.)

18. Pogosova G.V., Oganov R.G., Koltunov I.E. et al. Monitoring of secondary prevention of ischemic heart disease in Russia and European countries: results on international multicenter study EUROASPIRE III. Kardiologiia. 2011;1:34-40. (In Russ.)

19. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22. doi: 10.1016/S0140-6736(02)09327-3.

20. Shepherd L., Blauw G.J., Murphy M.B., et al. PROSPER study group. PROspective study of pravastatin in the elderly at risk. Pravastatin in elderly individuals at risk vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-30. doi: 10.1016/S0140-6736(02)11600-X.

21. Amarenco P., Bogousslavsky J., Amarenco P. et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-59. doi: 10.1056/NEJMoa061894.

22. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet. 2004;364:685-96. doi: 10.1016/S01406736(04)16895-5.

23. Susekov A.B., Zubarev M.Y., Deev A.D., et al. The main results of the Moscow Research on statins (Moscow Statin Survey, MSS). Serdtse. 2006;6:324-328. (In Russ.)

24. Shalnova S.A., Deev A.D. Research lessons the OSCAR epidemiology and features of therapy of patients of high risk in real clinical practice 2005-2006. Cardiovascular Therapy and Prevention. 2007;6(1):47-53. (In Russ.)

25. Oganov R.G., Pogosova G.V., Koltunov I.E. et al. RELIF Regular Treatment And Prevention a key to situation improvement with cardiovascular diseases in Russia: results of the Russian multicenter research. Pt II. Kardiologiia. 2007;47(11):30-9. (In Russ.)

26. Athyros V., Papageogiou A., Mercouris B. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus usual care in secondary coronary heart disease prevention. The GREACE study. Current Medical Research Opinion. 2002;18(4):220-8.

27. ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. 2013. J Am Coll Cardiol. 2014;1(63):2889-934. doi: 10.1016/j.jacc.2013.11.002.

28. 2012 ESH/ESC Practice Guidelines for the Management of Acute Myocardial Infarction in patients presenting with ST-segment elevation. European Heart Journal. 2012;33:2569-619. doi: 10.1093/eurheartj/ehs215.

29. 2012 ESH/ESC Practice Guidelines for the Management of Acute and Chronic Heart Failure. European Heart Journal. 2012;33:1787-847. doi: 10.1093/eurjhf/hfs105.

30. Boytsov S.A., Yakushin S.S., Martsevich S.Y. et al. In-patient and outpatient register of cardiovascular diseases in Ryazan Region (RECVASA): major tasks, formation experience, and first outcomes. Rational Pharmacotherapy in Cardiology. 2013;9(1):4-14. (In Russ.)

31. Martsevich S.Y., Gaysenok O.V., Tripkosh S.G. Medical supervision in specialized center and the quality of lipid lowering therapy in patients with cardiovascular diseases (according to the PROFIL register). Rational Pharmacotherapy in Cardiology. 2013;9(2):133-40. (In Russ.)

32. Tendera M., Fox K., Ferrari R. et al. Inadequate Heart Rate Control Despite Widespread Use of BetaBlockers in Outpatients With Stable CAD: Findings From the International Prospective CLARIFY Registry. Int J Cardiol. 2014;176(1):119-24. doi: 10.1016/j.ijcard.2014.06.052.

33. Tolpygina S.N., Polyanskaya Y.N., Martsevich S.Y., Treatment of patients with chronic coronary heart disease in real clinical practice according to the “IHD PROGNOSIS” registry data (Part 1). Rational Pharmacotherapy in Cardiology. 2013;9(2):138-42. (In Russ.)


For citation:


Fitilev S.В., Shkrebneva I.I., Vozzhaev A.V., Tsukanova K.O. FIVE-YEAR DYNAMICS OF SECONDARY PREVENTION IN PATIENTS WITH STABLE ANGINA AT SPECIALIZED OUT-PATIENT LEVEL IN MOSCOW (PHARMACOEPIDEMIOLOGY STUDY). Rational Pharmacotherapy in Cardiology. 2018;14(2):244-251. (In Russ.) https://doi.org/10.20996/1819-6446-2018-14-2-244-251

Views: 145


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)